Want to see KR:137310 full AI Analyst Report?
SD Biosensor, Inc. (137310) Stock Price & Analysis
137310 Stock Chart & Stats
- Day’s Range
- $6,200.00 - $6,390.00
- 52-Week Range
- $5,800.00 - $10,060.00
- Previous Close
- $6,280.00
- Volume
- N/A
- Average Volume (3M)
- 116.72K
- Market Cap
- KRW 752.05B
- Enterprise Value
- KRW 646.14B
- Total Cash (Recent Filing)
- KRW 408.07B
- Total Debt (Recent Filing)
- KRW 285.11B
- Price to Earnings (P/E)
- ―
- Beta
- 0.06
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 30, 2026
- Dividend Yield
- 3.15%
Bulls Say, Bears Say
Bulls Say
Revenue Stabilization
The meaningful TTM revenue rebound after the 2023 decline indicates that demand and commercial activity have begun to stabilize. If maintained, renewed top-line growth could improve operating leverage and provide a stronger foundation for recovering profitability over the next several quarters.
Manageable Leverage
Improving debt-to-equity and moderate overall leverage give SD Biosensor greater financial flexibility while it works through weak earnings. A sizable equity base can help absorb continued volatility and preserve capacity to support operations without relying excessively on additional borrowing.
Prior Cash Flow Recovery
The return to positive operating and free cash flow in 2024 and 2025 shows that the business has demonstrated an ability to convert operations into internally generated liquidity. That recovery can support funding needs and reduce dependence on external capital if cash generation remains durable.
Bears Say
Sustained Losses
Persistent losses across 2023 through TTM indicate that the revenue rebound has not yet translated into sustainable earnings. Widening TTM losses can consume equity over time, restrict reinvestment capacity, and make the company more vulnerable if operating conditions remain challenging.
Margin Compression
Repeated gross-margin compression suggests that incremental revenue is currently producing less economic value than in earlier periods. Unless margins stabilize, weaker unit economics will limit operating leverage, constrain future profit recovery, and make sustained earnings improvement more difficult.
Weaker Recent Cash Generation
The steep TTM decline in free cash flow reduces the liquidity cushion that had improved during 2024 and 2025. Weaker cash conversion relative to reported losses could limit internally funded investment and increase pressure on the balance sheet if the trend persists.
137310 FAQ
What was SD Biosensor, Inc.’s price range in the past 12 months?
What is SD Biosensor, Inc.’s market cap?
When is SD Biosensor, Inc.’s upcoming earnings report date?
How were SD Biosensor, Inc.’s earnings last quarter?
Is SD Biosensor, Inc. overvalued?
Does SD Biosensor, Inc. pay dividends?
What is SD Biosensor, Inc.’s EPS estimate?
How many shares outstanding does SD Biosensor, Inc. have?
What happened to SD Biosensor, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SD Biosensor, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
SD Biosensor, Inc.
SD Biosensor Inc is an in vitro diagnostic company. It is engaged in the immunochemical diagnosis, molecular diagnosis, point-of-care diagnosis (POCTs), and self blood glucose measurement business. The company researches and develops products such as rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, and enzyme immunological reaction diagnosis products.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Hyo Keun Lee
- Employees
- 656
- Website
- www.sdbiosensor.com
- Address
- 16 Deokyeong-daero, Suwon, GY, 16690, KR
SD Biosensor, Inc. (137310) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 12 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |